Tissue Transglutaminase in Marmoset Experimental Multiple Sclerosis: Discrepancy between White and Grey Matter

Nathaly Espitia Pinzon¹, Esther Stroo¹, Bert A. ‘t Hart²,³, John G. J. M. Bol¹, Benjamin Drukarch¹, Jan Bauer⁴, Anne-Marie van Dam¹*⁹

¹ VU University Medical Center, Neuroscience Campus Amsterdam, Department of Anatomy and Neurosciences, Amsterdam, The Netherlands, ² Biomedical Primate Research Center, Department of Immunobiology, Rijswijk, The Netherlands, ³ University Groningen, University Medical Center, Department of Neuroscience, Groningen, The Netherlands, ⁴ Center for Brain Research, Department of Neuroimmunology, Vienna, Austria

Abstract

Infiltration of leukocytes is a major pathological event in white matter lesion formation in the brain of multiple sclerosis (MS) patients. In grey matter lesions, less infiltration of these cells occur, but microglial activation is present. Thus far, the interaction of β-integrins with extracellular matrix proteins, e.g. fibronectin, is considered to be of importance for the influx of immune cells. Recent in vitro studies indicate a possible role for the enzyme tissue Transglutaminase (TG2) in mediating cell adhesion and migration. In the present study we questioned whether TG2 is present in white and grey matter lesions observed in the marmoset model for MS. To this end, immunohistochemical studies were performed. We observed that TG2, expressed by infiltrating monocytes in white matter lesions co-expressed β₁-integrin and is located in close apposition to deposited fibronectin. These data suggest an important role for TG2 in the adhesion and migration of infiltrating monocytes during white matter lesion formation. Moreover, in grey matter lesions, TG2 is mainly present in microglial cells together with some β₁-integrin, whereas fibronectin is absent in these lesions. These data imply an alternative role for microglia-derived TG2 in grey matter lesions, e.g. cell proliferation. Further research should clarify the functional role of TG2 in monocytes or microglial cells in MS lesion formation.

Introduction

Multiple Sclerosis (MS) is a chronic, inflammatory demyelinating disease of the human central nervous system (CNS), affecting mostly young adults in the prime of their lives [1]. Its clinical manifestation is characterized mainly by motor and sensory deficits, and most commonly has a relapsing-remitting course [2,3]. Although there is a debate on the immunological versus neurodegenerative origin of MS [4–6], it is well-established that the entry of leukocytes into the CNS is an important event in the pathophysiology of MS [7,8], in addition to glial cell activation [9–12]. In active white matter MS lesions, a disturbance of the blood-brain barrier function permits this influx of immunomodulatory cells, contributing to inflammation, demyelination and axonal damage evolving neurological deficits [13,14]. In grey matter lesions, the influx of immunomodulatory cells is rather limited, whereas activated microglial cells are present like in white matter lesions but to a lesser extent [15–22].

During MS white matter lesion formation, basement membranes, i.e. thin layers of connective tissue lining the perivascular space, and the brain parenchyma express various types of extracellular matrix (ECM) protein deposits, such as fibronectin (FN), an important ECM protein in MS lesions [23–25]. ECM proteins are generally important because they play a role in the recruitment of inflammatory cells by interacting with integrins expressed on activated leukocytes [26–28]. This interaction occurs via the recognition site amino acid motif Arg-Gly-Asp (RGD) that can be found within FN [29] and many other matrix proteins [30]. Of the integrins, αβ₁-integrin is the major cell surface integrin interacting with the RGD-cell binding site on FN, facilitating cell adhesion [31]. Of additional interest in this process is the multifunctional Ca²⁺-dependent enzyme tissue Transglutaminase (TG2). TG2 is expressed in the cytoplasm or surface of a wide variety of cells, and can be deposited in the ECM [32]. This enzyme, when activated, is able to bind and cross-link several ECM proteins, though its interaction with FN is best characterized [33]. More recently, it has become clear that various β-integrins can interact with TG2, forming β-integrin-TG2 complexes on the cell surface [34–36]. Consequently, TG2 is referred to as an
integrin-binding coreceptor for FN [37]. In this manner, TG2 can contribute to cell-matrix interactions such as cell adhesion and possibly other β integrin-dependent functions including cell spreading and migration of e.g. monocytes [38–40] that likely are of importance during MS lesion formation. In the present study, we therefore question whether TG2 is present in various lesion types in experimental autoimmune encephalomyelitis (EAE) in the common marmoset. This experimental animal model mimics relevant clinical symptoms and relevant inflammatory, glial, and demyelinating white and grey matter pathology associated with relapsing-remitting MS [5,41] which is uncommon in rodent models for MS [42,43]. To this end, we studied the presence of immunoreactive TG2 in white and grey matter lesions of marmosets suffering from EAE, identified the cell types expressing TG2, and related those to FN and β1-integrin expression.

Materials and Methods

Brain material from marmosets

For this study we obtained, with permission, brain material from marmosets (Callithrix jacchus) suffering from EAE, that had been involved in preclinical experiments on the refinement of the experimental autoimmune encephalomyelitis model (see also Table 1) [44]. The original studies were approved by the BPRC committee on Animal Experimentation (DEC; approval numbers 483, 512, 514), and carried out in strict accordance with their guidelines. In that study, all marmosets were housed in pairs in spacious cages enriched with branches and toys, and with padded shelter provided on the floor. They remained under veterinary care and clinical scoring was performed twice daily by trained observers, using a previously described semiquantitative scale [45]. The animals were sacrificed once their clinical signs reached the score of 2.5, e.g. paresis. We did not perform any animal experiments for this present study.

Histopathology

From formalin-fixed paraffin-embedded brains, coronal sections (3–5 μm) were cut and used for immunohistochemistry. Brain sections were deparaffinized by heating them at 56°C for 30 min. Sections were then rinsed three times for 10 min. in clear advantage (xylene replacement, Polyscience Inc., Warrington, United States) and subsequently immersed for 5 min. each in 100% ethanol (twice), 96% ethanol, 90% ethanol, 70% ethanol and demineralized water. The extent of inflammation was evaluated by staining for hematoxylin and eosin to visualize infiltrated cells and a staining for myeloid-related protein 14 (MRP14, BMA Biomedicals, Augst, Switzerland) was performed to visualize macrophages [46,47]. Moreover, a Klüver Barrera stain (Luxol Fast Blue (LFB) combined with periodic acid-Schiff (PAS)) was performed to examine myelin and myelin degradation products as previously described [45]. Images were taken using an Olympus-VANOX-T lightmicroscope (Tokyo, Japan).

TG2 immunoreactivity

After deparaffination, antigen retrieval was performed by incubating the sections in ethylenediaminetetraacetic acid (EDTA, pH = 9.0) buffer for 30 min. in a steaming device (MultiGourmet FS 20; Braun, Kronberg/Taunus, Germany). Subsequently, the sections were allowed to regain room temperature (RT), washed

Table 1. Lesion types per animal.

| Animal | Immunization antigen | Lesion type (number per type) |
|--------|----------------------|------------------------------|
| 1      | MOG34–56             | IA (3) + LA (2)              |
| 2      | MOG34–56             | EA (1) + IA (1) + LA (2)     |
| 3      | MOG34–56             | LA/IA (3) + EA/IA (1)        |
| 4      | MOG34–56             | LA (1)                       |
| 5      | MOG74–96 + MOG34–56  | EA/LA (1) + IA (1) + cGML (1)|
| 6      | MOG74–96 + MOG34–56  | EA/LA (1) + LA/IA (1) + IA(1)|
| 7      | MOG74–96 + MOG34–56  | LA/IA (1) + IA (1)           |
| 8      | MOG74–96 + MOG34–56  | LA (1) + cGML (2)            |

MOG: myelin oligodendrocyte glycoprotein, EA: early active, LA: late active, IA: inactive, cGML: cortical grey matter lesion.

Table 2. Combinations of primary and secondary antibodies used for immunoreactive labeling.

| Primary antibodies (see table 3) | Host | Dilutions | Secondary antibodies (see table 4) |
|-----------------------------------|------|-----------|-----------------------------------|
| Ab3 + β1-integrin                  | Mouse + Rabbit | 1:1000+1:1000 | 2+6                                |
| Ab3 + CD3                          | Mouse + Rabbit | 1:1000+1:800  | 2+6                                |
| Ab3 + FN                           | Mouse + Sheep  | 1:1000+1:1000 | 2+7                                |
| Ab3 + GFAP                         | Mouse + Rabbit | 1:1000+1:2000 | 2+4                                |
| Ab3 + Iba-1                        | Mouse + Goat   | 1:1000+1:600  | 2+1                                |
| Ab3 + Olig2                        | Mouse + Rabbit | 1:1000+1:750  | 2+6                                |
| Ab4 + CD20                         | Rabbit + Mouse | 1:400+1:50    | 5+3                                |

FN: fibronectin.

doi:10.1371/journal.pone.0100574.t002
three times in Tris-buffered saline (TBS, pH 7.4), 5 min. each, and endogenous peroxidase was blocked for 20 min. with 0.3% hydrogen peroxidase and 0.1% sodium azide in TBS. Sections were washed three times again with TBS for 5 min each. Non-specific binding sites were blocked with DAKO buffer (0.05 M Tris/HCl, 0.15 M NaCl, 0.05% Tween 20, pH 7.6, DAKO, Glostrup, Denmark) with 10% fetal calf serum (FCS) for 30 min. at room temperature. For TG2 staining, the sections were subsequently incubated overnight at 4°C with mouse anti TG2 (Ab3, Neomarkers; final dilution 1:15,000) diluted in DAKO buffer with 10% FCS. After washes in TBS, the sections were incubated for 2 hrs at RT in biotinylated donkey anti-mouse IgG (Jackson Laboratories; final dilution 1:500). After washes in TBS, sections were incubated for one hour in HRP-labeled avidin-biotin complex (1:100; Sigma, St. Louis, USA). Sections were washed twice with TBS and once with Tris-HCl (pH 7.6). Peroxidase activity was visualized by adding 3,3-diaminobenzidine (DAB, Sigma) as a substrate. Sections were washed twice with Tris-HCl and once with running tap water. Finally, sections were counterstained with haematoxylin and sections were washed three times in running tap water. After dehydration in graded ethanol solutions, the sections were cleared in xylene and coverslipped in Entellan (Merck, Darmstadt, Germany). Images were taken using an Olympus-VANOX-T light microscope.

Fluorescent double labeling procedures

Three different protocols were used for double labeling of TG2 with various antigens, decided by the fluorescent intensity of the stainings. After the preincubation step as described above, the sections for (1) double labeling of FN or the astrocyte marker glial fibrillar acidic protein (GFAP) with TG2 were incubated with the appropriate primary antibodies in 5% normal donkey serum in 0.5% Triton-X100 (TBS-T; pH 7.6, blocking solution) at 4°C overnight (see Tables 2 and 3). Subsequently, the sections were thoroughly washed in TBS, and incubated at room temperature for 2 hrs with appropriate Alexa Fluor 488 or Alexa Fluor 546, and Alexa Fluor 594 labeled IgG’s (see Tables 2 and 4); (2) double labeling of the B-cell marker CD20 or the oligodendrocytes marker Olig2 with TG2 were incubated with the appropriate primary antibodies in 5% normal donkey serum in TBS-T at 4°C overnight (see Tables 2 and 3). Thereafter, the sections were thoroughly washed in TBS, and incubated at room temperature for 2 hrs with appropriate biotinylated labeled IgG’s for CD20 or Olig2 (see Tables 2 and 4) and concomitantly with the appropriate Alexa Fluor 594 labeled IgG to stain for TG2. Thereafter, the sections were washed in TBS and finally incubated for 2 hrs at room temperature with Alexa Fluor 488 labeled-streptavidin (1:400, Molecular Probes, Breda, the Netherlands) to detect CD20 or Olig2; (3) double labeling of β1-integrin, the monocyte/macrophage/microglia Iba-1 or the T-cell marker CD3 with TG2 were incubated with the appropriate primary antibodies in 5% normal donkey serum in TBS-T at 4°C overnight (see Tables 2 and 3). Sections were then thoroughly washed, and incubated at room temperature for 2 hrs with the appropriate biotinylated labeled IgG’s for β1-integrin, Iba-1 or CD3 (see Tables 2 and 4) and concomitantly with the appropriate Alexa Fluor 594 labeled IgG to detect TG2. Sections were washed in TBS and incubated for one hour in ABC (1:500, ABC kit, Vectastain elite, Vector Laboratories Inc., Burlingame, CA, USA). Sections were then washed in TBS again and incubated with biotinylated tyramide (1:800, gift from dr. I. Huitinga, The Netherlands Institute for Neuroscience (NIN), Amsterdam, The Netherlands) in 0.005% H2O2 in TBS for 20 min. Sections were washed once more in TBS and incubated once more for 1 hr in ABC (1:800) and washed in TBS again. The last step in this adjusted protocol was incubation of the sections with Alexa Fluor 488 labeled-streptavidin (1:400, Molecular Probes) for 2 hrs to detect β1-integrin, Iba-1 or CD3. Finally, at the end of all 3 double labeling protocols, sections were washed in TBS and mounted in Vectashield (Vector laboratories Inc.). Immunofluorescence was examined using a Leica confocal laser scanning microscope (Leica TSC-SP2-AOBS; Leica Microsystems, Wetzlar, Germany). Omission of the primary antibodies served as a negative control.

Quantification of TG2 and Iba-1 positive cells

The number of TG2 and Iba-1 positive cells was quantified in inactive white matter lesions (12 lesions, from 7 different animals) and in early/late active lesions (8 lesions, from 6 different animals).

Table 3. Origin of primary antibodies used.

| Antigen                  | Host       | Manufacturer   |
|--------------------------|------------|----------------|
| Transglutaminase type 2  | Mouse      | NeoMarkers     |
| β1-integrin              | Rabbit     | Santa Cruz     |
| CD3 (pan T-lymphocytes)  | Rabbit     | DAKO           |
| CD20 (pan B-lymphocytes) | Mouse      | DAKO           |
| Fibronectin              | Sheep      | R&D systems    |
| GFAP (astrocytes)        | Rabbit     | DAKO           |
| Iba-1 (monocytes/macrophages/microglia) | Goat | Abcam          |
| Olig2 (oligodendrocytes) | Rabbit     | Millipore      |

Table 4. Secondary antibodies used.

| Number | Host | Target | Dilution | Labeled | Manufacturer   |
|--------|------|--------|----------|---------|----------------|
| 1      | Donkey | Goat   | 1:800    | Biotin  | Jackson        |
| 2      | Donkey | Mouse  | 1:400    | Alexa-594 | Mol. Probes   |
| 3      | Goat   | Mouse  | 1:800    | Biotin  | Jackson        |
| 4      | Donkey | Rabbit | 1:400    | Alexa-488 | Mol. Probes   |
| 5      | Donkey | Rabbit | 1:400    | Alexa-594 | Mol. Probes   |
| 6      | Goat   | Rabbit | 1:800    | Biotin  | Jackson        |
| 7      | Donkey | Sheep  | 1:400    | Alexa-546 | Mol. Probes   |
Figure 1. Characterization of marmoset EAE lesions and TG2 immunoreactivity. The normal appearing white matter (NAWM) shows an intact LFB myelin staining (A) and few MRP14 positive macrophages (G). Early active (EA) lesions display myelin degradation (B) and foamy macrophages (H). Late active (LA) lesions show degradation of myelin (C) combined with less MRP14 positive macrophages (I). Inactive (IA) lesions are characterized by an absence of both myelin staining (D) and MRP14 positive macrophages (J). The normal appearing grey matter (NAGM) shows intact myelin fibers (E) and very few MRP14 positive macrophages (K). Cortical grey matter lesions (cGML) show an absence of myelin fibers (F) and presence of MRP14 positive microglia (L). TG2 immunoreactivity is present in endothelium of the vessel walls in NAWM (M). Early active and late active lesions display additional TG2 positive cells (N and O respectively). Inactive lesions show less additional TG2 immunoreactivity (P). Cortical grey matter lesions also show additional TG2 positive cells (R) compared to the endothelial staining in normal appearing grey matter (Q). Scale bar is 20 μm.

doi:10.1371/journal.pone.0100574.g001
Characterization of marmoset EAE lesions

Normal appearing white and grey matter were defined by an intact myelin staining and few MRPl4 positive macrophages (Fig. 1A, G and Fig. 1E, K respectively) [46]. Early active white matter lesions were characterized by the abundant presence of macrophages with LFB positive myelin degradation products (Fig. 1B, H). Late active white matter lesions were identified by the presence of macrophages containing PAS positive myelin degradation and residual LFB positive myelin degradation products together with a diminished presence of MRPl4 positive macrophages (Fig. 1C, I). Inactive white matter lesions were identified by the presence of some PAS positive macrophages in the absence of LFB and MRPl4 positive macrophages (Fig. 1D, J). Cortical grey matter lesions were characterized by in the absence of myelin staining and an increase in MRPl4 positive microglial cells (Fig. 1F, L). The number and type of EAE lesions varied between and within animals (Table 1).

TG2 immunoreactivity is present in marmoset EAE lesions

In normal appearing white and grey matter, TG2 immunoreactivity was hardly present except in the endothelium of the vessel walls [Fig. 1M, Q], as described before in rodent and human brain [48–51]. In the various EAE white matter lesions types, additional TG2 immunoreactivity was observed in cells with a rounded morphology located mostly near blood vessels. The signal intensity of TG2 immunoreactivity was not uniform in all positive cells, suggesting different TG2 expression levels. Early and late active lesions showed a considerable amount of TG2 immunoreactive cells throughout the lesion (Fig. 1N, O). In inactive lesions less TG2 positive cells per white matter sample area of 0.1 mm² was about 3 times higher than in inactive lesions (Fig. 2A). In addition, TG2 immunoreactivity appeared in cortical grey matter lesions (Fig. 1R). The majority of TG2 positive cells showed a small cell body with thin, radially projecting processes.

TG2 is expressed by monocytes/microglial cells in marmoset EAE lesions

Iba-1 positive cells were observed in all types of EAE lesions (Fig. 3B, E, H, K). These cells showed Iba-1 immunoreactivity on the cell surface as described previously [52,53]. TG2 immunoreactivity was mainly localized in the cytoplasm (Fig. 3A, D, G, J). Co-labeling of Iba-1 with TG2 showed Iba-1 positive/TG2 positive cells with a rounded morphology with no clear processes in early (Fig. 3C) and late active white matter lesions (Fig. 3F). Note that not all Iba-1 positive cells express TG2. Based on the morphology of the TG2 positive/Iba-1 positive cells we cannot determine whether these are microglial cells with an amoeboid morphology or infiltrating monocytes, although their localization close to a blood vessel favors the latter option. After quantification, we determined that the number of Iba-1 positive cells per white matter sample area of 0.1 mm² in early/late active lesions was about 2 times higher than in inactive lesions (Fig. 2B). Additionally, co-labeling of Iba-1 with TG2 seemed less apparent in inactive EAE lesions (Fig. 3I) compared to the co-labeling observed in the active EAE lesions, which is likely a consequence of the reduced number of TG2 and Iba-1 positive cells (Fig. 2). Co-labeling of TG2 with Iba-1 positive cells was also found in cortical grey matter lesions (Fig. 3L). Interestingly, besides the presence of some TG2 positive monocyte-like cells, the morphology of the majority of TG2/ Iba-1 positive cells was largely different from those seen in the white matter lesions, and reflected more ramified microglial cells (Fig. 1R).

TG2 is not expressed in astrocytes, oligodendrocytes, T- and B-lymphocytes

To examine whether also non-myeloid cell types expressed TG2 in various marmoset EAE white matter lesions, additional immunofluorescent double labeling experiments were performed. Co-labeling for TG2 and GFAP was absent, indicating that astrocytes did not express TG2 in EAE lesions (Fig. 4A, E, I). Similarly, Olig2 positive oligodendrocytes appeared negative for TG2 (Fig. 4B, F, J). Moreover, TG2 immunoreactivity was neither

Statistics

Data were analyzed by a Student's t-test for unpaired independent measurements by using the SPSS 15.0 for Windows statistical program (SPSS, Inc., Chicago IL). P < 0.05 was considered to represent statistically significant differences.
present in CD3 positive T-lymphocytes (Fig. 4C, G, K) nor in CD20 positive B-lymphocytes (Fig. 4D, H, L).

**β1-integrin and FN immunoreactivity in relation to TG2 positive cells in marmoset EAE lesions**

We further studied whether β1-integrin and/or FN showed co-labeling with TG2 in marmoset EAE lesions, since TG2 has been referred to as an integrin-binding coreceptor for FN in previous *in vitro* studies [37,54]. Compared to control (Fig 5A) β1-integrin immunoreactivity was increased in all EAE lesion types, (Fig. 5B-D). Double labeling experiments showed the presence of β1-integrin particularly on the cell surface of a subset of TG2 positive cells, specifically in active white matter lesions (Fig. 5C, C'). Also in grey matter lesions, β1-integrin was present in or on TG2 positive cells. Although not quantified, it appeared that amoeboid-shaped cells expressed more β1-integrin than ramified microglial cells (Fig. 5E).

FN immunoreactivity was hardly present in NAWM (Fig. 5F), but was clearly increased in active white matter lesions and increased to a lesser extent in inactive lesions (Fig. 5G-I). FN was found to be partly cell-associated, and was mostly present in the ECM in these lesions (Fig. 5G-I). Double labeling experiments for FN and TG2 showed little co-labeling, but clearly close association of TG2 positive monocytes with extracellular FN in the matrix was seen most prominent in active white matter lesions (Fig. 5H, H').

In grey matter lesions, there was little FN immunoreactivity present (Fig. 5J).

**Discussion**

The present study shows appearance of TG2 immunoreactivity in monocyte and microglial-like cells in early active white matter, and active grey matter marmoset EAE lesions. When white matter lesions progress to late active and inactive stages, TG2 immunoreactivity is still present, but in the inactive lesions it is significantly less pronounced. In addition, in white matter lesions, TG2 positive monocytes co-label with β1-integrin, and are in close apposition to, mostly extracellular located, fibronectin. In grey matter lesions, TG2 positive microglia co-label with β1-integrin, but no fibronectin is present.

For this study we were able to obtain material from marmosets suffering from EAE. This primate has high genetic similarity to humans. Its mature immune system, shaped by life-long exposure to environmental and latent infections, resembles the human immune system. The MS-like disease phenotype and pathology of marmoset EAE is therefore a useful model to investigate if certain factors, in this case TG2, contribute to the pathogenesis of MS [55].

In active white matter lesions, we observed the appearance of the enzyme TG2, particularly located around blood vessels where leukocytes infiltrate into the CNS during the EAE disease process.
The number of these TG2 positive cells reduces when the lesions lose activity. This reduction occurs simultaneously with the reduction of Iba-1 positive cells in the CNS at this time [56–59]. Based on co-labeling studies, TG2 was found to be present in Iba-1 positive infiltrating monocytes in white matter lesions in marmoset EAE. Moreover, we recently observed major histocompatibility complex (MHC) II positive monocyte-like cells to express TG2 immunoreactivity in active white matter MS lesions (unpubl. data). Thus infiltrating monocytes seem to represent an important source of TG2 in MS/EAE active white matter lesions within the CNS. In grey matter lesions, TG2 appeared preferentially in microglial cells. Microglial-derived TG2 has also been described in gerbil hippocampal grey matter after transient ischemia [60]. This suggests that lesioned grey matter areas express TG2 preferentially in microglial cells. Thus far, TG2 has been shown to be expressed by a wide variety of cell types, both in vivo and in vitro [32].

**Figure 4. TG2 is not expressed in astrocytes, oligodendrocytes, T-cells and B-cells.** TG2 immunoreactivity (red) is not present in GFAP (green; A, E, I), Olig2 (green; B, F, J), CD3 (green; C, G, K) or CD20 (green; D, H, L) positive cells in early (EA), late active (LA) and inactive (IA) lesions. Scale bar is 20 μm.

doi:10.1371/journal.pone.0100574.g004
lesions on the cell surface of a subset of TG2 (red) positive cells.

In early (EA), late (LA) active lesions and inactive (IA) white matter

immunoreactivity is present in grey matter lesions (J). Arrows represent
(TG2/FN double labeled cells. Scale bar is 20 μm. Inserts in the inserts are 10 μm.
doi:10.1371/journal.pone.0100574.g005

Figure 5. β1-integrin and fibronectin immunoreactivity show
coe-presence with TG2 positive cells in marmoset EAE lesions.
β1-integrin (A) and fibronectin (FN) (F) immunoreactivity (green) is
found in normal appearing white matter (NAWM) near TG2 (red) in the
endothelium of the vessel walls. β1-integrin (green; B, C, C', D) appears
in early (EA), late (LA) active lesions and inactive (IA) white matter
lesions on the cell surface of a subset of TG2 (red) positive cells. β1-
integrin also shows some co-localization with TG2 positive cells in
cortical grey matter lesions (cGML) (E, E'). Arrows represent TG2/β1-
integrin double labeled cells. FN (green; G, H, H', I) appears clearly in the
extracellular matrix but also shows co-labeling with a subset of TG2
(red) positive cells in early and late active lesions. Hardly any FN
immunoreactivity is present in grey matter lesions (J). Arrows represent
TG2/FN double labeled cells. Scale bar is 20 μm. Inserts in figures C', E'
and H' represent higher magnifications in which the close association
of TG2 positive cells with β1-integrin or FN (C', E' or H', respectively) can
be appreciated. Scale bars in the inserts are 10 μm.
leukocytes [18,83–85]. These data suggest that TG2 expressed by microglial cells in active grey matter lesions is probably not implicated in immune cell infiltration or migration. Of interest is that integrin expression has been demonstrated on microglial cells in MS lesions [86], and subsequent in vitro studies revealed a role for β1-integrin in microglial cell proliferation [57]. Indeed, in MS lesions, microglial and monocyte proliferation have been observed [88]. We thus propose that the TG2/β1-integrin positive microglial cells in the grey matter lesions are or have been prone to proliferation.

In conclusion, the observed appearance of immunoreactive TG2 in monocytes in active white matter lesions during marmoset EAE, in combination with its co-expression with β1-integrin and close association to extracellular FN, strongly suggests an important role for TG2 in the adhesion, migration and/or differentiation of infiltrating monocytes during EAE, and possibly MS. The appearance of TG2 in microglial cells in grey matter lesions together with β1-integrin, suggests an alternative role, e.g. microglial proliferation. Our novel observations on TG2 expression in white and grey matter lesions in a highly relevant animal model for MS are of interest in better understanding the possible functional implications TG2 may have in the pathogenesis of white and grey matter lesions in MS.

Author Contributions
Conceived and designed the experiments: NEP AMD. Performed the experiments: ES BAH JGMB JB. Analyzed the data: NEP. Contributed reagents/materials/analysis tools: BAH JB. Contributed to the writing of the manuscript: NEP BD JB AMD.

References
1. Weinshenker BG, Bious B, Rice GPA, Noseworthy J, Carrière W, et al. (1989) The natural history of multiple sclerosis: a geographically based study I. clinical course and disability. Brain 112: 133–146.
2. Noseworthy JH, Lucchinetti CF, Rodriguez M, Weinshenker BG (2000) Multiple Sclerosis. The New England Journal of Medicine 343: 938–952.
3. Engel C, Greim B, Zett UK (2007) Diagnostics of cognitive dysfunctions in multiple sclerosis. Journal of Neurology 254 Suppl: I30–4.
4. Trapp BD, Nave K-A (2008) Multiple sclerosis: an immune or neurodegenerative disorder? Annual Review of Neuroscience 31: 247–269.
5. Eichler MJ, Osborn L, Takahira Y, Crouse G, Luhowskyj S, et al. (1990) VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 60: 377–384.
6. Ley K, Laudeh C, Cybulsky MI, Nourshargh S (2007) Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nature Reviews Immunology 7: 678–689.
7. Bauer M, Brakebusch C, Cosne C, Sixt M, Wekerle H, et al. (2009) Beta1 integrin differentially controls extravasation of inflammatory cell subsets into the CNS during autoimmunity. Proceedings of the National Academy of Sciences of the United States of America 106: 1920–1925.
8. Pierschbacher M, Hayman EG, Ruoslahti E (1983) Synthetic peptide with cell attachment activity of fibronectin. Proceedings of the National Academy of Sciences of the United States of America 80: 1224–1227.
9. Van Horssen J, De Vries HE (2007) The extracellular matrix in multiple sclerosis pathology. Journal of Neurochemistry 103: 1293–1301.
10. Eichler MJ, Osborn L, Takahira Y, Crouse G, Luhowskyj S, et al. (1990) VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 60: 377–384.
11. Sriram S (2011) Role of glial cells in innate immunity and their role in CNS pathology, mechanisms and therapeutic implications. Current Opinion in Immunology 23: 153–161.
12. Lassmann H (2014) Mechanisms of white matter damage in multiple sclerosis. Acta Neurologica Scandinavica 120: 51–57.
13. Stys PK, Zamponi GW, Van Minnen J, Geurts JJG (2012) 24. Van Horssen J, Dijkstra CGD, De Vries HE (2007). The extracellular matrix in multiple sclerosis pathology. Journal of Neurochemistry 103: 1293–1301.
14. Eichler MJ, Osborn L, Takahira Y, Crouse G, Luhowskyj S, et al. (1990) VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 60: 377–384.
15. Ley K, Laudeh C, Cybulsky MI, Nourshargh S (2007) Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nature Reviews Immunology 7: 678–689.
16. Bauer M, Brakebusch C, Cosne C, Sixt M, Wekerle H, et al. (2009) Beta1 integrin differentially controls extravasation of inflammatory cell subsets into the CNS during autoimmunity. Proceedings of the National Academy of Sciences of the United States of America 106: 1920–1925.
17. Bø L (2009) The histopathology of grey matter demyelination in multiple sclerosis. Acta Neuropathologica 120: 51–57.
18. Bø L, Vedeler CA, Nyland H, Trapp BD, Mørk S (2003) Transected neurites, astrocytes and microglia in models of multiple sclerosis. Clinical & Developmental Immunology 2009: 1–15.
19. Gray E, Thomas TL, Betmouni S, Scolding N, Love S (2008) Elevated activity of microglial cells in active grey matter lesions is probably not implicated in immune cell infiltration or migration. Of interest is that integrin expression has been demonstrated on microglial cells in MS lesions [86], and subsequent in vitro studies revealed a role for β1-integrin in microglial cell proliferation [57]. Indeed, in MS lesions, microglial and monocyte proliferation have been observed [88]. We thus propose that the TG2/β1-integrin positive microglial cells in the grey matter lesions are or have been prone to proliferation.

In conclusion, the observed appearance of immunoreactive TG2 in monocytes in active white matter lesions during marmoset EAE, in combination with its co-expression with β1-integrin and close association to extracellular FN, strongly suggests an important role for TG2 in the adhesion, migration and/or differentiation of infiltrating monocytes during EAE, and possibly MS. The appearance of TG2 in microglial cells in grey matter lesions together with β1-integrin, suggests an alternative role, e.g. microglial proliferation. Our novel observations on TG2 expression in white and grey matter lesions in a highly relevant animal model for MS are of interest in better understanding the possible functional implications TG2 may have in the pathogenesis of white and grey matter lesions in MS.
67. Wilhelmus MMM, Van Dam A-M, Drukarch B (2008) Tissue transglutaminase.

65. Lesort M, Chun W, Johnson GVW, Ferrante RJ (1999) Tissue Transglutaminase Is Increased in Huntington’s Disease Brain. Journal of Neurochemistry 72: 134–142.

63. Junn E, Ronchetti RD, Quezado MM, Kim S, Mouradian MM (2003) Tissue transglutaminase colocalizes with extravascular matrix proteins in cerebral amyloid angiopathy. Neurobiology of Aging 24: 1159–1169.

60. Hwang IK, Yoo K-Y, Yi SS, Kim IY, Hwang HS, et al. (2009) Expression of tissue transglutaminase in astrocytes in multiple sclerosis. The New England Journal of Medicine 361: 134–142.

59. Van der Valk P, De Groot CJ (2000) Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathology and Applied Neurobiology 26: 2–10.

58. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mo¨rk S, et al. (1998) Axonal transection in the lesions of multiple sclerosis. The New England Journal of Medicine 339: 890–897.

57. Popescu BFGH, Lucchinetti CF (2012) Pathology of demyelinating diseases. European Journal of Pharmacology 585: 464–472.

55. ‘t Hart BA, Gran B, Weissert R (2011) EAE: imperfect but useful models of neurodegenerative diseases. European Journal of Pharmacology 585: 464–472.

54. Akimov SS, Belkin AM (2001) Cell-surface transglutaminase promotes fibronectin assembly via interaction with the gelatin-binding domain of fibronectin: a role in TGFbeta-dependent matrix deposition. Journal of Cell Science 114: 2989–3000.

53. Imai Y, Kohsaka S (2002) Intracellular signaling in M-CSF-induced microglia activation: role of Bax. Glia 40: 164–174.

51. De Jager M, Van der Wildt B, Schul E, Bol JGJM, Van Duinen SG, et al. (2013) Transglutaminase Type II Is Involved in the Pathogenesis of Endotoxic Shock. Immunology 174: 7330–7340.

50. Colak G, Johnson GVW (2012) Complete transglutaminase 2 ablation results in a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative disorders. Frontiers in Bioscience 12: 891–904.

47. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H (1996) Distinct patterns of tissue transglutaminase during early multiple sclerosis lesions. Annals of Neurology 38: 788–796.

46. Bruck W, Porada P, Poser S, Rieckmann P, Haundfeld F, et al. (1995) Monocyte/macrophage differentiation in early multiple sclerosis lesions. Annals of Neurology 38: 788–796.

45. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H (1996) Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathology 6: 259–274.

44. Thomazy V, Fesus L (1989) Differential expression of tissue transglutaminase in human cells. Cell and Tissue Research 255: 215–224.

43. Gaudry CA, Verderio E, Jones RA, Smith C, Griffin M (1999) Tissue transglutaminase is an important player at the surface of human endothelial cells: evidence for its externalization and its colocalization with the beta(1) integrin. Experimental Cell Research 252: 104–113.

42. Colak G, Johnson GVW (2012) Complete transglutaminase 2 ablation results in a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative disorders. Frontiers in Bioscience 12: 891–904.